Pharmexcil, the Pharmaceuticals Export Promotion Council of India, has intensified collaborations with key government bodies including the Department of Commerce, Department of Pharmaceuticals, and DGFT to sustain and accelerate the sector’s export growth. With FY25 exports hitting $30.47 billion (9.4% YoY increase), the council is focusing on policy alignment, MSME integration, innovation, and trade facilitation to navigate global challenges and target higher trajectories.
Glimpse:
High-level engagements emphasize easing trade processes, boosting MSME participation in global supply chains, and fostering industry-academia ties in clinical research, biopharma, vaccines, and APIs. India’s domestic market (~$60 billion) is projected to reach $130 billion by 2030, while exports supply over 150 countries. Pharmexcil remains optimistic amid stabilizing global demand, prioritizing quality, sustainability, and diversification.
India’s pharmaceutical export sector has crossed a significant threshold, reaching $30.47 billion in FY 2024-25 with a robust 9.4% year-on-year growth, solidifying its position as the world’s “pharmacy.” To maintain this momentum, the Pharmaceuticals Export Promotion Council of India (Pharmexcil) has deepened partnerships with central government departments, conducting strategic meetings to chart a forward-looking roadmap.
Pharmexcil engaged senior officials from the Department of Commerce and Industry, Department of Pharmaceuticals (DoP), and Directorate General of Foreign Trade (DGFT). These discussions centered on aligning policies, streamlining trade procedures, promoting innovation, and expanding micro, small, and medium enterprises (MSMEs) in exports recognizing MSMEs as vital for inclusive growth and global supply chain integration.
With DoP, focus areas included strengthening industry-academia collaborations in clinical research, biopharmaceuticals, vaccines, and active pharmaceutical ingredients (APIs), alongside skill development to fuel R&D. DGFT talks prioritized trade facilitation measures to enhance ease of doing business for exporters.
India’s pharma exports now reach over 150 countries, underscoring reliable, affordable supply chains. The domestic market stands at ~$60 billion, eyed to triple to $130 billion by 2030. Despite pricing pressures and regulatory hurdles, Pharmexcil expresses optimism: stabilizing global healthcare demand positions the sector to sustain and exceed current levels.
This government-industry synergy highlights proactive efforts to address challenges like import dependence on APIs/components, while leveraging strengths in generics and formulations. Upcoming events like iPHEX 2026 will further amplify global outreach.
“The council remains optimistic about sustaining and surpassing current pharma export levels as global healthcare demand stabilises.”
By
HB Team
